The Bottom Line: So … rewards are for what – increasing dilution on top of their exorbitant salaries and – some call this a BUY! Shame … no wonder the RegMed universe is going … where? If this isn’t a SELL – what is?
It would seem as though we have some paid bashers in the house today. Welcome, welcome! We so do love a good jest now and again. Enjoy your time here, basher #$%$, and don't forget to buy a little stock for yourselves while you're at it ;)
McCusker is clueless. This is what he said about Athersys months ago:
"I am still shying away from companies that are over-loaded with pre-clinical development programs such as ATHX, CUR, PSTI and STEM."
We will have interim results from 2 Phase II PoC trials in the next 12 months and will start a Phase II/III trial in GVHD once we hear back from the FDA in the few weeks.
Amazing how ignorant some folk are. :(